These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38938013)

  • 1. New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.
    Pourriyahi H; Hajizadeh N; Khosravi M; Pourriahi H; Soleimani S; Hosseini NS; Mohammad AP; Goodarzi A
    Immun Inflamm Dis; 2024 Jun; 12(6):e1323. PubMed ID: 38938013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
    Terpos E; Musto P; Engelhardt M; Delforge M; Cook G; Gay F; van de Donk NWCJ; Ntanasis-Stathopoulos I; Vangsted AJ; Driessen C; Schjesvold F; Cerchione C; Zweegman S; Hajek R; Moreau P; Einsele H; San-Miguel J; Boccadoro M; Dimopoulos MA; Sonneveld P; Ludwig H
    Leukemia; 2023 Jun; 37(6):1175-1185. PubMed ID: 37142661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
    Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
    Curr Drug Targets; 2024; 25(8):517-525. PubMed ID: 38726782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
    Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
    Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Fotakis EA; Petrone D; Del Manso M; Siddu A; Stefanelli P; Bella A; Riccardo F; Rezza G; Palamara AT; Brusaferro S; Pezzotti P;
    Euro Surveill; 2023 Aug; 28(32):. PubMed ID: 37561053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
    J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
    J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
    Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
    J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.